Atreo, the leader in next-generation Randomization and Trial Supply Management (RTSM) technology, today announced the successful launch of its 100th study. Reaching this milestone reflects growing ...
Review authors suggested guidelines to help in standardizing future lupus nephritis studies. Heterogeneity in lupus nephritis (LN) trial design substantially hinders interpretation of studied drugs’ ...
Adia Nutrition, Inc. (OTCQB: ADIA), a publicly traded company based in Winter Park, Florida, dedicated to advancing ...
Alcoholic beverages in the United States carry a warning label, but you’d be forgiven if they leave little impression. In ...
Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost ...
FDA authorization supports a mid-stage clinical evaluation of CK0802 in steroid-refractory GVHD, where steroid nonresponse is ...
Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrolling; ASPENOVA designed as confirmatory study to support DENALI Phase ...
Finding and developing new molecules is one of the great research endeavors of modern chemistry. From the development of new ...
I read with great interest the recent article by Taylor et al published in The American Journal of Managed Care, which ...
Scientists have developed a breakthrough injectable biomaterial that travels through the bloodstream to repair damaged tissue ...
Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically ...
Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-RAnnounced positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results